Skip to main content
. 2016 Dec 28;8(6):9466–9475. doi: 10.18632/oncotarget.14326

Figure 1. OSI-027 potentiates AT406's cytotoxicity in HCC cells.

Figure 1

Established HCC cell lines (HepG2 and SMMC-7721) or the primary human HCC cells (two lines, “HCC-1/-2”) were treated with AT406 (see molecular structure in (A) at applied concentrations) or plus OSI-027 (“OSI”, 100 nM), cells were further cultured and subjected to MTT assay (B, D–F) or clonogenic assay (C, for HepG2 cells) to evaluate cell survival. Data were means of three independent experiments ± SD (Same for all figures). IC-50 was calculated by the GraphPad Prism software using a sigmoidal dose-response curve model. CalcuSyn software was utilized to calculate Combination Index (CI). “Ctrl” indicated untreated control group (Same for all figures). *indicated statistically significant differences as compared to “Ctrl” group. #indicated statistically significant differences as compared to “AT406” only group.